Glypican-3-mediated inhibition of CD26 by TFPI: A novel mechanism in hematopoietic stem cell homing and maintenance

Blood

Volumn 121, Issue 14, 2013, Pages 2587-2595

  Khurana, Satish ^a   Margamuljana, Lia ^a   Joseph, Chacko ^a   Schouteden, Sarah ^a   Buckley, Shannon M ^a   Verfaillie, Catherine M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV; GLYPICAN 3; PROTEOHEPARAN SULFATE; STROMAL CELL DERIVED FACTOR 1; TISSUE FACTOR PATHWAY INHIBITOR; DPP4 PROTEIN, HUMAN; DPP4 PROTEIN, MOUSE; GLYPICAN; GPC3 PROTEIN, HUMAN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL HOMING; CHIMERA; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; STEM CELL NICHE; UMBILICAL CORD BLOOD; WESTERN BLOTTING; ANIMAL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CELL MOTION; CHEMOTAXIS; CYTOLOGY; FEMALE; HEMATOPOIESIS; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RADIATION EXPOSURE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; CELLS, CULTURED; CHEMOTAXIS; DIPEPTIDYL PEPTIDASE 4; ENDOTHELIAL CELLS; FEMALE; GLYPICANS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS;

MLCS; MLOWN;

EID: 84878218848     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-456715     Document Type: Article

References (43)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17): 1813-1826.
2. Gluckman E, Rocha V, Boyer-Chammard A, et al. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337(6):373-381.
3. Bernstein ID, Delaney C. Engineering stem cell expansion. Cell Stem Cell. 2012;10(2):113-114.
4. Dellatore SM, Garcia AS, Miller WM. Mimicking stem cell niches to increase stem cell expansion. Curr Opin Biotechnol. 2008;19(5):534-540.
5. Morrison SJ, Spradling AC. Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life. Cell. 2008;132(4): 598-611.
6. Mazo IB, Gutierrez-Ramos JC, Frenette PS, et al. Hematopoietic progenitor cell rolling in bone marrow microvessels: Parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med. 1998;188(3):465-474.
7. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999; 283(5403):845-848.
8. Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD341 hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD341 progenitors to peripheral blood. J Exp Med. 1997; 185(1):111-120.
9. Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6): 977-988.
10. Jung Y, Shiozawa Y, Wang J, et al. Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol. 2011;39(2): 151-166.
11. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307-1318.
12. Delgado MB, Clark-Lewis I, Loetscher P, et al. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol. 2001;31(3):699-707.
13. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276(47):43503-43508.
14. Shioda T, Kato H, Ohnishi Y, et al. Anti-HIV-1 and chemotactic activities of human stromal cellderived factor 1alpha (SDF-1alpha) and SDF- 1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A. 1998;95(11):6331-6336.
15. Christopherson KW II, Hangoc G, Mantel CR, et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004; 305(5686):1000-1003.
16. Tian C, Bagley J, Forman D, et al. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther. 2006; 13(7):652-658.
17. Christopherson KW 2nd, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD341 or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 2007;16(3):355-360.
18. Buckley SM, Ulloa-Montoya F, Abts D, et al. Maintenance of HSC by Wnt5a secreting AGM-derived stromal cell line. Exp Hematol. 2011;39(1):114-123.
19. Panteleev MA, Zarnitsina VI, Ataullakhanov FI. Tissue factor pathway inhibitor: A possible mechanism of action. Eur J Biochem. 2002; 269(8):2016-2031.
20. Tjwa M, Sidenius N, Moura R, et al. Membraneanchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. J Clin Invest. 2009;119(4):1008-1018.
21. Mast AE, Higuchi DA, Huang ZF, et al. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J. 1997; 327(Pt 2):577-583.
22. Davoodi J, Kelly J, Gendron NH, et al. The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics. 2007; 7(13):2300-2310.
23. Winkler IG, Barbier V, Wadley R, et al. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: Serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood. 2010;116(3):375-385.
24. Zhang CC, Lodish HF. Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells. Blood. 2004;103(7):2513-2521.
25. Hendrikx PJ, Martens CM, Hagenbeek A, et al. Homing of fluorescently labeled murine hematopoietic stem cells. Exp Hematol. 1996; 24(2):129-140.
26. Zigmond SH, Hirsch JG. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med. 1973;137(2):387-410
27. Taylor IW. A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem Cytochem. 1980;28(9):1021-1024.
28. Szilvassy SJ, Meyerrose TE, Ragland PL, et al. Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood. 2001;98(7):2108-2115.
29. Frenette PS, Subbarao S, Mazo IB, et al. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci U S A. 1998;95(24):14423-14428.
30. Mazo IB, Massberg S, von Andrian UH. Hematopoietic stem and progenitor cell trafficking. Trends Immunol. 2011;32(10):493-503.
31. Rahfeld J, Schierhorn M, Hartrodt B, et al. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV?. Biochim Biophys Acta. 1991;1076(2):314-316.
32. Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86(4):959-972.
33. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7):687-694.
34. Wolf M, Albrecht S, Märki C. Proteolytic processing of chemokines: Implications in physiological and pathological conditions. Int J Biochem Cell Biol. 2008;40(6-7):1185-1198.
35. Filmus J, Church JG, Buick RN. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol. 1988;8(10):4243-4249.
36. Pellegrini M, Pilia G, Pantano S, et al. Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn. 1998;213(4):431-439.
37. Paine-Saunders S, Viviano BL, Zupicich J, et al. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol. 2000;225(1):179-187.
38. Jackson SM, Nakato H, Sugiura M, et al. dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development. 1997;124(20):4113-4120.
39. Song HH, Shi W, Filmus J. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem. 1997; 272(12):7574-7577.
40. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245-6254.
41. Broxmeyer HE, Hoggatt J, O'Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786-1796.
42. Morange PE, Simon C, Alessi MC, et al. PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004;109(11): 1343-1348.
43. Udagawa K, Yasumitsu H, Esaki M, et al. Subcellular localization of PP5/TFPI-2 in human placenta: A possible role of PP5/TFPI-2 as an anticoagulant on the surface of syncytiotrophoblasts. Placenta. 2002;23(2-3):145-153.